A detailed history of Washington Trust Advisors, Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Washington Trust Advisors, Inc. holds 308 shares of VRTX stock, worth $154,754. This represents 0.01% of its overall portfolio holdings.

Number of Shares
308
Previous 313 1.6%
Holding current value
$154,754
Previous $146,000 2.05%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

SELL
$460.0 - $505.78 $2,300 - $2,528
-5 Reduced 1.6%
308 $143,000
Q2 2024

Jul 25, 2024

SELL
$392.81 - $485.53 $24,747 - $30,588
-63 Reduced 16.76%
313 $146,000
Q1 2024

May 07, 2024

SELL
$407.69 - $446.08 $65,638 - $71,818
-161 Reduced 29.98%
376 $157,000
Q4 2023

Jan 18, 2024

SELL
$343.0 - $410.68 $11,319 - $13,552
-33 Reduced 5.79%
537 $218,000
Q3 2023

Oct 18, 2023

SELL
$338.18 - $362.46 $2,029 - $2,174
-6 Reduced 1.04%
570 $198,000
Q2 2023

Jul 27, 2023

SELL
$314.42 - $351.91 $40,245 - $45,044
-128 Reduced 18.18%
576 $202,000
Q1 2023

May 04, 2023

BUY
$283.23 - $323.1 $15,294 - $17,447
54 Added 8.31%
704 $221,000
Q4 2022

Feb 08, 2023

SELL
$285.76 - $321.48 $450,072 - $506,331
-1,575 Reduced 70.79%
650 $187,000
Q3 2022

Oct 14, 2022

SELL
$273.83 - $305.53 $45,181 - $50,412
-165 Reduced 6.9%
2,225 $644,000
Q2 2022

Jul 25, 2022

SELL
$234.96 - $292.55 $149,669 - $186,354
-637 Reduced 21.04%
2,390 $673,000
Q1 2022

May 05, 2022

SELL
$221.42 - $260.97 $122,223 - $144,055
-552 Reduced 15.42%
3,027 $790,000
Q4 2021

Feb 11, 2022

BUY
$177.01 - $223.45 $633,518 - $799,727
3,579 New
3,579 $786,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Washington Trust Advisors, Inc. Portfolio

Follow Washington Trust Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Washington Trust Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Washington Trust Advisors, Inc. with notifications on news.